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ABSTRACT: Class I major histocompatibility complex (MHC-
I)-bound peptide ligands dictate the activation and speciﬁcity of
CD8+ T cells and thus are important for devising T-cell
immunotherapies. In recent times, advances in mass spectrom-
etry (MS) have enabled the precise identiﬁcation of these
MHC-I peptides, wherein MS spectra are compared against a
reference proteome. Unfortunately, matching these spectra to
reference proteome databases is hindered by inﬂated search
spaces attributed to a lack of enzyme restriction in the searches,
limiting the eﬃciency with which MHC ligands are discovered.
Here we oﬀer a solution to this problem whereby we developed
a targeted database search approach and accompanying tool SpectMHC, that is based on a priori-predicted MHC-I peptides. We
ﬁrst validated the approach using MS data from two diﬀerent allotype-speciﬁc immunoprecipitates for the C57BL/6 mouse
background. We then developed allotype-speciﬁc HLA databases to search previously published MS data sets of human
peripheral blood mononuclear cells (PBMCs). This targeted search strategy improved peptide identiﬁcations for both mouse and
human ligandomes by greater than 2-fold and is superior to traditional “no enzyme” searches of reference proteomes. Our
targeted database search promises to uncover otherwise missed novel T-cell epitopes of therapeutic potential.
KEYWORDS: mass spectrometry, MHC ligandome, CD8 T-cell epitopes, immunotherapy, database searching
■ INTRODUCTION
Antigen-speciﬁc activation of CD8+ T-cells is initiated when a
speciﬁc T-cell receptor recognizes its cognate peptide epitopes
presented through class I major histocompatibility complexes
(MHC-I) on antigen presenting cells. These MHC-bound
peptides, collectively known as the MHC-I ligandome, are
usually 8−11 amino acids long and are derived from
intracellular-cleaved “self” or foreign proteins.1 MHC-I
molecules, termed Human Leukocyte Antigens (HLA) in
humans, are highly polymorphic, particularly in the human
population, and the peptides bound are highly dependent on an
individual’s HLA allotype. Surveying the MHC-I ligandome in
both a context- and allotype-speciﬁc manner is of the utmost
importance in understanding how the adaptive immune
response is regulated in pathogen infection and cancer.
Furthermore, precise MHC-I peptide identiﬁcation from mass
spectrometry (MS) data is especially important in designing
therapeutic targets that could be used to formulate personalized
CD8+ T-cell-based therapies such as vaccines against infectious
diseases.2 Additionally, for vaccine-based cancer immunothera-
pies, MS-enabled identiﬁcation of tumor-associated MHC-I
ligands or those containing neo-antigens is crucial.3,4
Identifying MHC-I ligands by MS remains diﬃcult due to
low peptide abundance, but advancements in MS sensitivity are
revolutionizing the process. Currently, the main experimental
approach is to perform immuno-precipitation (IP) of MHC-I
proteins, followed by peptide elution, puriﬁcation, and analysis
by LC−MS/MS.5 For mouse models, well-characterized MHC-
I allotype-speciﬁc antibodies can be employed in the IP because
allelic diversity in mice is low. In contrast, human allelic
diversity is high but pan-HLA-speciﬁc antibodies such as the
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W6/32 antibody are well established.6 Spectra from the
antibody eluates are then scored against a protein database
using search algorithms such as Mascot and ﬁltered to a certain
false discovery rate (FDR). Following the database searches, it
is common for a large portion of the collected spectra to not be
assigned a peptide identiﬁcation. Recently, this has been
partially attributed to unforeseen proteasomally spliced
peptides nonexistent in the database searches.1 In the past,
other types of nonstandard MHC-I peptides have also been
reported that may explain missing spectral assignments in
database searches such as noncanonical reading frames7 and
nonclassical peptide cleavage.8 However, another common
problem that complicates spectral assignments in all MHC
ligandome analyses to date is the inability to narrow the
number of potential spectral matches by specifying a proteolytic
enzyme cleavage speciﬁcity, as would be implemented when
searching shotgun proteomics data. As a result, vast search
spaces are explored during database searches of MHC-I IP MS
data because the composition of peptide assignments tested is
not representative of the sample. As such, statistical power is
low when estimating FDRs for MS/MS spectra. It has been
proposed for proteomics studies that search space sizes could
be reduced by limiting them to only those peptides likely to be
present in the sample.9,10 This strategy would improve FDR
estimations and increase the number of peptides identiﬁed from
shotgun MS data. We therefore questioned whether the search
spaces for MHC-I IP MS database searches could be limited
solely to predicted MHC-I ligands for the allotypes of the
sample to improve identiﬁcation rates.
Various MHC-I peptide prediction tools are available to
implement the MHC-peptide database search approach.11−14
Most predictors are trained on existing MHC-I binding assay
data and output lists of potential MHC-I peptides from protein
sequences.15 One such tool, NetMHC,12 uses neural networks
trained on large data sets of MHC-I peptide binding aﬃnity
values and predicts probable MHC-I ligands for queried
proteins. Executing NetMHC in mouse models is practical
because few allotypes exist among mouse MHC-I proteins.
Although polymorphism of human alleles is high, performing
HLA predictions is now becoming feasible as peptide-binding
data sets are being collected on more allotypes.16
Here we developed a targeted database search strategy using
NetMHC predictions to compile peptide databases to search
MHC-I IP MS data. The approach leads to greatly improved
numbers of MHC class I peptide identiﬁcations from both
murine and human IPs. To implement the targeted searches,
we made an accompanying Python-based tool, SpectMHC,
available to the immunology community. On the basis of a
reference proteome, SpectMHC compiles targeted MHC-I
peptide FASTA databases to be used for searching MHC-I IP
MS data and is available on GitHub: https://github.com/
Prathyusha-konda/SpectMHC. It is worth noting that our
approach not only is applicable to current and future MHC
ligand discovery eﬀorts but also can be used retrospectively;
when we applied it to already published MHC ligandome data




EL4 cells were originally purchased from ATCC and were
maintained in Dulbecco’s modiﬁed Eagle medium (Invitrogen,
Waltham, MA), containing 10% FBS (Invitrogen) and 5%
antibiotic/antimycotic (Invitrogen). Cells were grown in T75
ﬂasks to a density of 2 × 106 cells/mL before subculturing or
harvesting for experiments.
Mouse MHC-I and Human HLA Peptide Database
Compilation
Mouse and human FASTA databases were downloaded from
UniProtKB (mouse, December 2015; human, February 2015),
containing all mouse or human proteins including isoforms and
variants. Using an oﬄine version of NetMHC (version 4.0),
allotype-speciﬁc mouse or human binding aﬃnities were
predicted for all 8-, 9-, 10-, and 11-mer peptides for 2 mouse
allotypes (H-2 Db and H-2 Kb) and 14 human allotypes (A*01,
A*02, A*03, A*11, A*24, A*29, A*32, B*07, B*08, B*27,
B*35, B*39, B*44, and B*51). All peptides with NetMHC-
predicted binding aﬃnities ≤2% rank for each allotype were
then compiled into a new FASTA database. All database
manipulations were performed using Python and R scripts.
MHC-I Peptide Immuno-Precipitation
An aliquot of 8 × 108 EL4 cells was pelleted and used for
MHC-I peptide immuno-precipitation as previously de-
scribed.17 In brief, cells were lysed in PBS containing 0.4%
CHAPS and mini-complete protease inhibitor tablets (Roche,
Indianapolis, IN). Antibodies were produced in-house from
hybridoma clones B22.249 (H-2 Db-speciﬁc) and Y3 (H-2 Kb-
speciﬁc). MHC-I proteins were precipitated from the cell lysate
using 2 mg of each antibody coupled to 80 mg of CNBr-
activated Sepharose 4B resin (Uppsala, Sweden). Incubations
were performed overnight at 4 °C in 10 mL glass tubes. Bound
MHC-I proteins and peptides were washed with 40 mL of PBS,
then 30 mL of Milli-Q water, and then eluted eight times with
200 μL of 0.2% triﬂuoroacetic acid (TFA). Eluates were ﬁltered
through 3 kDa molecular weight cutoﬀ ﬁlters (Millipore, Cork,
Ireland); then, the ﬁltrate was lyophilized and desalted using
Stage-tips.18
Mass Spectrometry
Lyophilized peptides were solubilized in 12 μL of 1% formic
acid and analyzed by LC−MS/MS. For each antibody eluate, an
aliquot of 1 μL of peptides was injected onto a 75 μm × 30 cm
column (New Objective, Woburn, MA) self-packed with 4 μm,
90 Å, Proteo C18 material (Phenomenex, Torrance, CA).
Online chromatography was performed using a Dionex
Ultimate 3000 UHPLC (Thermo-Scientiﬁc, San Jose, CA) at
a ﬂow rate of 300 nL/min. Peptides were separated and eluted
into the mass spectrometer using a gradient of 3 to 35%
acetonitrile (0.1% formic acid) over 65 min, followed by 5 min
at 95% acetonitrile (0.1% formic acid). MS was performed
using an Orbitrap Velos Pro (Thermo-Scientiﬁc, San Jose, CA)
operated in data-dependent mode. Survey scans (MS1) were
performed using the Orbitrap over a scan range of 350−650 m/
z and resolution setting of 60 000. A lock mass of 445.12003
m/z was used to achieve internal mass calibration as previously
described.19 On the basis of MS1 scans, MS2 scans were
performed using the ion trap, selecting the top 10 most intense
precursor (MS1) ions for fragmentation by collision-induced
dissociation (CID) at 35% collision energy with a precursor
isolation window of 2 m/z. MS2 scans were only collected on
peptides with charge states of 2+ or 3+ with a minimum MS1
intensity of 50 counts. Advanced gain control (AGC) settings
were 5 × 105 for Orbitrap scans and 2 × 105 for ion trap scans.
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Database Searching and Comparisons
Mouse and human database searches were performed using
either Sequest or Mascot implemented with Proteome
Discoverer 1.4. The parent ion (MS1) tolerance was 5 ppm
and fragment ion tolerance was 0.5 Da. Spectra for each IP
were searched against either the parent database (Parent-DB)
or the MHC-targeted database (MHC-DB or HLA-DB).
Spectra were searched against Parent-DB using no enzyme
speciﬁcity but searched against MHC-DB or HLA-DB using no
cleavage restriction. Peptide FDR was controlled using
Percolator. All peptides with “medium” (5% FDR) or “high”
(1% FDR) conﬁdence were reported in the ﬁnal data sets.
Peptide and Peptide Spectral Match (PSM) analyses comparing
results for the diﬀerent antibody eluates and database searches
were performed using R. Mouse MS (.raw) ﬁles have been
deposited to Chorus, https://chorusproject.org, ID#1098.
Code Availability
We have made SpectMHC available on GitHub: https://github.
com/Prathyusha-konda/SpectMHC. This semicommand-line-
based tool is customized to be used with preinstalled stand-
alone NetMHC packages, in Darwin (Mac) and Linux
platforms. The tool takes an input protein FASTA database
and outputs predicted MHC-binding peptides using NetMHC
4.0, NetMHC 3.4, or NetMHCpan. The instructions to utilize
the code are available in the readme ﬁle found in the above
GitHub folder.
■ RESULTS AND DISCUSSION
Generation of Targeted MHC-I Databases
Improving MHC peptide ligand identiﬁcation and measure-
ment by MS is important because MHC-I peptides are not
produced from easily predictable enzymatic cleavage sites. This
leads to all peptides within a speciﬁc precursor ion tolerance
being tested, resulting in large search spaces that most likely
result in inﬂated FDR statistics and low speciﬁcity. It has been
proposed that the assignment of spectra from shotgun MS
experiments can be improved by tailoring the search database
to those peptides likely to be in the sample.9,20 Even in the
proteomics ﬁeld, recent attempts have been made to narrow
search spaces to improve protein identiﬁcations from peptide
digests by, for example, using databases formed from spectral
libraries of previously identiﬁed peptides10 or from RNASeq
data collected from the samples.21 In these cases, the targeted
searches resulted in databases that more accurately reﬂected the
samples analyzed and increased the number of identiﬁed
peptides. We thus anticipated that this targeted strategy could
be employed to reduce the complexity of databases used for
MHC-I IP MS searches. Searches against a targeted MHC-I
peptide database could then be implemented in which the
MHC prediction tool replaces enzymatic cleavage speciﬁcity.
Such a strategy allows the use of a no cleavage search, whereby
spectra are only tested against full database entries and not to
non-MHC peptides residing in the sequences therein. This is
exempliﬁed by the predicted MHC peptide, FQALNAEKL
from the mouse protein kinase ATR (Figure 1A), where instead
of the many matches to the full protein when using a no
enzyme search, a no cleavage search of the targeted database
Figure 1. Predicting MHC-I peptides for the full mouse proteome. (A) Targeted MHC-I search (MHC-DB), performed with no cleavage speciﬁcity,
limits potential spectral matches and decreases the search space compared with a reference proteome (Parent-DB) search. (B) Beginning with a
reference database of mouse proteins, a targeted MHC-I- database (MHC-DB) solely containing predicted sequences was formed (NetMHC ≤ 2%
rank) using SpectMHC. The MHC-DB contained peptides from the H-2 Db and H-2 Kb mouse alleles. Shown are the numbers of 8- to 11-mer
peptide sequences in the parent database and the total NetMHC-predicted peptides (H-2 Db and H-2 Kb). (C) Distribution of the total NetMHC-
predicted (≤2% rank) mouse MHC-I peptides (by 8- to 11-mers) for the H-2 Db and H-2 Kb allotypes used to create the MHC-DB.
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results in fewer potential matches to unlikely spectral
assignments.
We began with a simple mouse model for which the MHC-I
peptides could be easily predicted due to their low MHC-I
allelic polymorphism. The commonly used C57BL/6 labo-
ratory mouse strain carries the well-characterized H-2 Db and
H-2 Kb mouse MHC-I allotypes, for which hybridomas
producing allele-speciﬁc antibodies exist. To generate a targeted
MHC-I database, we used a “parent” reference database
containing 56 479 mouse UniProtKB protein sequences
(Parent-DB). Although many other tools are available such as
SYFPEITHI14 and IEDB,13 we have employed NetMHC for
peptide predictions because it has high allotype coverage.
Furthermore, in situations where the HLA alleles in question
are not covered by NetMHC 4.0, the pan-allotype-speciﬁc
NetMHCpan 3.0 predictor performs very well.22 Using
NetMHC (oﬄine, version 4.0), we predicted the H-2 Db and
H-2 Kb binding aﬃnities for all possible 8-, 9-, 10-, and 11-mer
peptides for each protein in the parent database (Figure 1B).
Rather than a speciﬁc nM aﬃnity cutoﬀ, a % rank cutoﬀ in
NetMHC has recently been shown to be more versatile across
diﬀerent allotypes, whereby the top 2% ranking predicted MHC
peptides show high speciﬁcity.22 Therefore, all 8- to 11-mer
peptides were ﬁltered to ≤2% NetMHC rank. This vastly
smaller list of peptides was compiled into a targeted, MHC-I
peptide database (MHC-DB) (Figure 1B). The MHC-DB is
Figure 2. Targeted MHC-I peptide database search increases MHC ligandome identiﬁcations. (A) Schematic for an allotype-speciﬁc, two-antibody
experiment to assess the MHC-DB search. H-2 Db and H-2 Kb-speciﬁc antibodies (B22.249 and Y3, respectively) were used to immuno-precipitate
MHC-I proteins from mouse EL4 cells (carrying the H-2 Db and H-2 Kb allotypes), followed by elution of peptides, separation from MHC-I proteins
by a cutoﬀ ﬁlter, and analysis by LC−MS/MS. Spectra were assigned using Sequest and Mascot and false discovery rates (FDRs) determined using
Percolator with either the Parent-DB or MHC-DB. (B) Parent-DB search results for mouse EL4 cells at 1% FDR, showing purity and allotype
speciﬁcity of the B22.249 and Y3 antibodies. Shown separately for each allele-speciﬁc IP (and the total of both) are the number of unique peptides
considered H-2 Db binders (NetMHC ≤ 2% rank for H-2 Db), H-2 Kb binders (NetMHC ≤ 2% rank for H-2 Kb), or nonbinders (NetMHC > 2%
rank, gray). (C) Comparison of the MHC-I peptides (NetMHC ≤ 2% rank) identiﬁed using the targeted MHC-DB search approach with both
Sequest and Mascot compared to the no enzyme Parent-DB search (1% FDR).
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composed of 1 458 851 entries of which H-2 Db peptides were
38% 8- to 9-mers whereas H-2 Kb peptides were 67% 8- to 9-
mers (as illustrated in Figure 1C). The MHC-DB contained
only 1% of the 8- to 11-mers in the Parent-DB (Figure 1B);
thus the potential peptide identiﬁcations in the search space
decreased by ∼2 orders of magnitude. It is clear that MHC-I
searches against this database would successfully limit the
search space to a small fraction of the mouse proteome. Using
the database for searching MS data also replaces the need for an
enzymatic cleavage speciﬁcity because it is inherently built into
the database prediction step. The targeted database allows for a
novel, simpliﬁed search strategy for MHC-I database searches
to increase ligand identiﬁcation. Because it would be of interest
to others, we oﬀer a supporting tool (SpectMHC) to make
searchable targeted MHC-I FASTA databases.
Targeted MHC-I Peptide Database Searches Increase
Identiﬁcation Rates for MHC-I Ligands
With the mouse MHC-I peptide FASTA database in hand, we
then empirically tested the targeted MHC-I database search
strategy. As a model, we used the EL4 mouse cell line (C57BL/
6 background) and performed allotype-speciﬁc MHC-IP
experiments using established protocols.17 Speciﬁcity was
enabled using antibodies speciﬁc to the H-2 Db (B22.249
hybridoma23) or H-2 Kb (Y3 hybridoma24) mouse allotypes
(Figure 2A). Following antibody-based MHC molecule elution
and peptide separation, peptide mass spectra were generated
using shotgun LC−MS/MS. An issue with limiting the search
space only to MHC-I peptides is that non-MHC peptides may
be falsely matched to MHC-I peptides because non-MHC
matches are not present. To test this, we intentionally did not
separate NetMHC-predicted H-2 Db and H-2 Kb predictions.
This strategy allowed us to assess whether non-MHC peptides
would be matched to the MHC-DB because correct peptide
matches from each IP should reﬂect the speciﬁcity of the
antibody used. Alternatively, if peptide matches to the MHC-
DB search were incorrect, then new peptide assignments
should be equally distributed among H-2 Db and H-2 Kb
peptides independent of the antibody.
To estimate false discovery rates for peptide identiﬁcation,
commercial software implementations of tools such as
Percolator25 are common and use reversed or shuﬄed versions
of the peptides as decoy databases. Using the MHC-I peptide-
targeted approach, a decoy database of reversed peptides can be
formed either before or after NetMHC prediction. Reversing
proteins before predicting requires an additional round of
NetMHC prediction and requires specifying target and decoy
databases during the search, which in most commercial
database search tools is not yet implementable. Before
implementing our searches with commercial software (Pro-
teome Discoverer) we manually assessed the target decoy
strategy, comparing Sequest search PSMs where the decoy was
formed by (1) reversing proteins in the Parent-DB then
predicting by NetMHC (Reverse then Predict) or (2) reversing
the NetMHC-predicted peptides (Predict then Reverse). We
observed the overall distribution (by Sequest XCorr) of target
and decoy hits (PSMs) to be similar by both strategies for both
the B22.249 and Y3 IPs (Supplementary Figure 1A).
Furthermore, in our 2-antibody model both approaches
accurately returned target PSMs of the correct antibody (H-2
Db to B22.249 and H-2 Kb to Y3), whereas decoy PSMs were
equally represented by the correct or incorrect allele-matching
PSMs (Supplementary Figure 1B). Manual estimation of the
FDR as previously described26 showed only minor diﬀerences
in the total number of unique peptides from each target decoy
strategy, and antibody allotype was conserved at 5%
(Supplementary Figure 1C) and 1% FDR (Supplementary
Figure 1D). As such, the approach could be implemented using
a single forward NetMHC-predicted database, which allowed
implementing Percolator in Proteome Discoverer whereby
reversed MHC peptides served as the decoy database.
To assess the EL4 MHC-I IP for the study, we ﬁrst
performed database searches against Parent DB using both
Sequest and Mascot with no enzyme as the search speciﬁcity,
with both 5% and 1% Percolator25 FDR thresholds. Using
Sequest/Percolator at 1% FDR a total of 1537 unique peptides
were identiﬁed between the B22.249 and Y3 antibody IPs.
Using Mascot/Percolator at 1% FDR, a total of 995 unique
peptides were identiﬁed between the B22.249 and Y3 antibody
IPs. Of these, only 8.9% (150) and 12.6% (126) of the Sequest
and Mascot searches, respectively, were not considered MHC-I
peptides using a 2% NetMHC rank cutoﬀ (Figure 2B).
Furthermore, the IPs were allotype-speciﬁc, in that MHC-I
peptides identiﬁed from the Sequest Parent-DB search were
97% (845/868) H-2 Db-speciﬁc and 90% (668/742) H-2 Kb-
speciﬁc (as revealed by a 2% NetMHC rank cutoﬀ) for the
B22.249 and Y3 IPs, respectively (1% FDR) (Figure 2B).
MHC-I peptides identiﬁed from the Mascot Parent-DB search
were 98% (471/482) H-2 Db-speciﬁc and 88% (370/422) H-2
Kb-speciﬁc for B22.249 and Y3 IPs, respectively (1% FDR)
(Figure 2B). At 5% Percolator FDR, a total of 2238 and 1942
peptides were identiﬁed by Sequest and Mascot searches,
respectively, of which 250 (11%) and 252 (13%) were not
considered MHC-I peptides by NetMHC (2% rank cutoﬀ),
respectively (Supplementary Figure 2A). Interestingly, even at
this much less stringent FDR (5%), antibody speciﬁcity was
similarly maintained as it was at 1% FDR. MHC-I peptides
identiﬁed from the Sequest Parent-DB search were 97% (1062/
1092) H-2 Db-speciﬁc and 89% (894/1008) H-2 Kb-speciﬁc (as
revealed by a 2% NetMHC rank cutoﬀ) for B22.249 and Y3
IPs, respectively (Supplementary Figure 2B). MHC-I peptides
identiﬁed from the Mascot Parent-DB search were 98% (911/
934) H-2 Db-speciﬁc and 88% (747/850) H-2 Kb-speciﬁc (as
revealed by a 2% NetMHC rank cutoﬀ) for B22.249 and Y3
IPs, respectively (Supplementary Figure 1B). Next, to test the
targeted search approach, we performed Sequest and Mascot
searches to match the MHC-IP spectra using no cleavage
search speciﬁcity against the MHC-DB. These searches resulted
in drastic improvements in unique MHC-I peptide identi-
ﬁcations compared with the Parent-DB, speciﬁcally for the
Mascot results: 3.9 and 3.6 fold for the B22.249 and Y3 IPs,
respectively, and 3.7 fold across the total unique H-2 Db and H-
2 Kb peptides identiﬁed (1% FDR in Figure 2C, 5% FDR in
Supplementary Figure 2B, Supplementary Data 1). Importantly,
we ﬁnd that Mascot searches with no cleavage also resulted in
higher numbers of unique peptides compared with Sequest
searches with no cleavage (Figure 2C, Supplementary Figure
2B). Matching non-MHC peptides to the MHC-DB was not
evident based on maintenance of allotype-speciﬁcity, whereby
96 and 91% of the peptides identiﬁed from the Sequest MHC-
DB searches matched the appropriate antibody for the B22.249
(H-2 Db-speciﬁc) and Y3 (H-2 Kb-speciﬁc) IPs, respectively
(Figure 2C). For the Mascot searches, 90 and 84% of the
peptides identiﬁed matched the appropriate antibody for the
B22.249 and Y3 IPs, respectively (Figure 2C). As such, these
peptides are assumed to be correct, and using the targeted
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search approach was successful. Accordingly, maintenance of
allotype-speciﬁcity was also observed at 5% FDR for both
Sequest and Mascot (Supplementary Figure 2B). We also
created MHC-DBs using 1, 5, and 10% rank as NetMHC
cutoﬀs, and a few additional peptides were identiﬁed with
increased % rank cutoﬀs (Supplementary Figure 3A,B). Further
support of these MHC-I peptide assignments is evident from
the distribution of binding aﬃnities; 85 and 84% of Mascot
MHC-DB search peptides were considered strong binders
(NetMHC ≤ 0.5% rank) for the B22.249 H-2 Db and Y3 H-2
Kb peptides, respectively (Supplementary Figure 4A). These
data are particularly supportive because the % rank for MHC-
DB peptides (≤2%) of all lengths was distributed relatively
evenly (Supplementary Figure 4B). Taken together, these data
show the potential for targeted database searches (particularly
Mascot) in solving the “no enzyme” problem for MHC-I
peptide identiﬁcations.
Increased MHC-I Ligand Identiﬁcations Are Due to
Enhanced Statistical Power
In previous studies where the search space was reduced,
increased numbers of identiﬁed peptides were mostly attributed
to better statistical power when performing FDR estimation.20
Poor statistical power and sensitivity is especially a concern for
searching MS data from MHC-I IPs using no enzyme
restriction. In such searches, the likelihood of getting a high-
scoring incorrect match to a peptide not likely present in the
sample is higher than with enzyme-restricted databases. As a
result, false-positive estimates appear higher and fewer matches
meet a required cutoﬀ. In our mouse data, we examined our
Mascot search results, which showed the greatest boost in
performance, and we observed that when peptides identiﬁed in
both the Parent-DB and MHC-DB search types are compared,
99.3 and 94.1% of Percolator q values (FDR estimates) are
lower for the MHC-DB search than the Parent-DB search for
the B22.249 and Y3 IPs, respectively (Figure 3A). Percolator
posterior error probabilities (PEPs), similar metrics to q values,
showed similar decreases (Supplementary Figure 5A).
Furthermore, across all identiﬁed peptides, Percolator q values
and PEP were also distributed lower in the MHC-DB search
(Figure 3B, Supplementary Figure 5B). Performing the MHC-
DB search thus improves statistical power for MHC IP
searches, which, taken together with the aforementioned
maintenance of allotype speciﬁcity, suggests that the approach
is sensitive but also accurate. Furthermore, by performing the
MHC-DB search, we were able to assign MS/MS spectra with
lower Mascot ions scores (1% FDR in Figure 3C, 5% FDR in
Supplementary Figure 6), which often occur when measuring
peptides of low abundance such as MHC-I peptides.
Interestingly, the approach also rescued the identiﬁcation of
many high Mascot-scoring spectra because they were identiﬁed
only in the MHC-DB search (exempliﬁed in Figure 4). As such,
a mechanistic explanation for the improved peptide identi-
ﬁcation rates is the higher sensitivity occurring from decreasing
the search space size to more accurately represent the sample.
Figure 3. Eﬀect of a targeted MHC database on search statistics. (A) Percolator q values for each peptide identiﬁed in both search types are plotted
in numerical order according to their Parent-DB q values. Percentages are the peptides for which the q value of the MHC-DB search was less than
the Parent-DB search. (B) Distribution of the Percolator q values (shown up to 5% FDR) for each MHC-IP search result, comparing Parent-DB and
MHC-DB search types. (C) Distribution and mean values of Mascot ions scores among identiﬁed peptides (1% FDR) for the Parent-DB and MHC-
DB search types for the B22.249 and Y3 IPs.
Journal of Proteome Research Technical Note
DOI: 10.1021/acs.jproteome.6b00971
J. Proteome Res. 2017, 16, 1806−1816
1811
HLA-Speciﬁc Database Searches Improve Statistical Power
and Peptide Identiﬁcations in Human HLA-IP Searches
Having established the MHC-DB search approach in a mouse
model, we next assessed the use of the targeted approach in
human-derived samples. To test this approach, we retrieved
eight MS/MS raw data ﬁles from recently published HLA
ligandome data collected from peripheral blood mononuclear
cells (PBMCs) of patients.27,28 We thus compiled targeted
HLA databases for searching human HLA ligandome data
based on the HLA-A and HLA-B allotypes of the patients. As in
the mouse experiments, we began with a human reference
proteome (Parent-DB) and used NetMHC to predict allotype-
speciﬁc HLA peptides (NetMHC ≤ 2% rank) forming a
targeted HLA database for each patient allotype (HLA-DB).
Using a 2% rank cutoﬀ, representation of predicted 8- to 11-
mer peptides was similar to that of the mouse databases
(Supplementary Figure 7A). The Parent-DB search showed
that most identiﬁed peptides were HLA binders (as revealed by
a NetMHC rank ≤2%) (Supplementary Figure 7B). Depending
on the patient sample, Mascot searching against the HLA-DB
resulted in 1.2- to 2.3-fold increases in HLA peptides compared
with the Parent-DB (at 1% FDR) (Figure 5A, Supplementary
Data 2). As in the mouse experiments, peptide identiﬁcation
increases can also be attributed to better statistical power
estimation because Percolator q values were again lower for the
HLA-DB search than for the Parent-DB search for all PBMC
samples (Figure 5B). Using the HLA-DB searches also enabled
the identiﬁcation of peptides with lower Mascot ions scores on
average (Figure 5C). The success of the targeted approach to
increase HLA peptide identiﬁcation in human samples is
important because they may bear a host of important
immunotherapeutic antigens.
MHC-I Peptides Assigned with the Targeted Databases Are
Not Contaminant Peptides
Arguably, a potential pitfall of performing the MHC-targeted
database search is that spectra identiﬁed as non-MHC-binding
peptides (most likely contaminant peptides) could be falsely
assigned as MHC-I peptides. The occurrence of these
contaminant assignments can be discerned by performing a
standard no enzyme search against the reference database.
Examination of the PSM overlap between the Parent-DB and
MHC-DB searches shows that few PSMs are solely identiﬁed
by the Parent-DB (Supplementary Figure 8). In this regard, we
found that only 12/118 of B22.249 and 8/180 of those Y3
peptide spectrum matches (PSMs) considered nonbinders in
the Parent-DB searches were reassigned as binders by the
MHC-DB search (at 1% FDR) (Figure 6A). In the human data,
of the nonbinder PSMs from the Parent-DB search, again few
were reassigned to HLA-binding peptides in the HLA-DB
search (Figure 6B). These PSMs can be ﬂagged for removal
during routine practice of the targeted approach, and overall,
the strategy still leads to a net increase in conﬁdent MHC-I or
HLA peptide assignments. It is not known how much of this
net increase comes at the cost of true MHC/HLA peptides not
Figure 4. Examples of spectra assigned by only the MHC-DB search. Shown are several MS/MS spectra with high Mascot ions scores from the (A)
B22.249 and (B) Y3 IPs that were not assigned to a peptide in the Parent-DB searches but assigned to peptides in the MHC-DB searches. Such
peptides were mostly allotype-speciﬁc (B22.249 peptides were ≤2% NetMHC rank for the H-2 Db allele; Y3 peptides were ≤2% NetMHC rank for
the H-2 Kb allele).
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predicted by NetMHC, but true binders should be further
interrogated by validation methods, iteratively improving the
prediction tools. Such may be the case for HLA-C allotypes,
which were not available from the PBMC data and are more
poorly studied. Taken together with the maintenance of
allotype speciﬁcity in the mouse experiment, these data also
support the notion that non-MHC-I binders will not match the
MHC-DB. We therefore propose that the targeted approach is
a superior option for identifying MHC-I ligands from MS data
as a result of its enhanced statistical power and will reveal
otherwise unidentiﬁed ligands. The targeted approach could
also bolster patient-speciﬁc immunotherapies because it is
Figure 5. Targeted HLA database searches increase peptide identiﬁcations in human PBMC class I HLA ligandome data. Publically available human
class I HLA ligandome raw data were retrieved and reanalyzed using searches based on allotype-speciﬁc targeted HLA databases. For each PBMC,
HLA peptides were predicted from a human reference proteome database (Parent-DB) using NetMHC (≤2% rank) based on the patient allotype as
stated in the publication.28 A patient-speciﬁc targeted HLA database search was performed and compared to the reference database (Parent-DB)
using Mascot and Percolator. (A) Peptide identiﬁcation increases (1% FDR) for each PBMC data set comparing the targeted HLA database (HLA-
DB) to the reference (Parent-DB) search. (B) For each PBMC ligandome search, Percolator q values (up to 5% FDR) are shown for peptides (all
allotypes) identiﬁed using both the Parent-DB and HLA-DB search. Peptides are plotted in numerical order according to their q value in the Parent-
DB search. Each PBMC number matches to that in the previously reported data set (Orbitrap data only).28 (C) Distribution and mean values of
Mascot ions scores among identiﬁed peptides (1% FDR) for the Parent-DB and HLA-DB search types for human PBMC ligandome data sets.
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conceivable that targeted databases could be based on patient
sequence data, improving the likelihood of detecting, for
example, neoantigen peptides in cancer.29
■ CONCLUSIONS
MHC ligandomes hold information on therapeutic targets
essential for understanding antigen-speciﬁc, T-cell-mediated
immunity. Exciting recent developments in antitumor immu-
notherapy involving T-cell-based therapeutics, including PD-1
and CTLA4 immune checkpoint inhibitors, have led to a
renewed importance for MHC-I ligand identiﬁcation,30 with
their potential for use as peptide vaccines. Database search
strategies for identifying MHC ligand mass spectra from LC−
MS/MS experiments were initially intended to be employed by
matching spectra to predictable protein fragments cleaved by
proteolytic enzymes.31 This leads to a lack of enzymatic
cleavage speciﬁcity in the search and is one of the many
potential reasons why the success rate in assigning peptide
identiﬁcations to ligand mass spectra data is low. Here, by
compiling databases limited to predicted MHC-I peptides, we
have greatly reduced the spectral search space. This approach
essentially replaces the proteolytic peptides with predicted
MHC-I ligands so that search strategies can be implemented as
originally intended. As mentioned, unassigned spectra in MHC-
I ligand studies could result from IP of nonclassical ligands that
our approach does not consider such as those proteasomally
spliced,1 which have recently been introduced as being
widespread. Furthermore, it is not known to what extent
proteasomal splicing, peptide bulging, or post-translational
modiﬁcations play in the ability of peptides to be predicted by
NetMHC. It is worth noting that many newly discovered
proteasomally spliced peptides were not considered binders by
NetMHC1 but might be better predicted as more is known
about them. Although novel peptide motifs missed as part of
our predictive approach can be recovered by performing a
complementary nontargeted search, caution should be taken in
combining iterative searches unless a global FDR is properly
considered.32 Future approaches should address how to
combine such searches. Overall, however, the targeted approach
is eﬀective for most scenarios, and as pan-allotype prediction
tools are improving over time,33 targeted database searches will
only improve. Furthermore, advances in MS speed and
sensitivity, alongside better MHC-I IP methodologies, will
result in the acquisition of even greater numbers of quality
spectra. Finally, this novel targeted database search approach
could be extended to other non-MHC-based investigations,
such as using motif-targeted databases composed of known
kinase phosphorylation motifs, thus improving phospho-
peptide identiﬁcation rates. We ultimately suggest that the
targeted database search for MHC-I peptide identiﬁcation is an
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